A PHASE 1 STUDY TO EVALUATE THE SAFETY, PROLIFERATION AND PERSISTENCE OF GEN-011, AN AUTOLOGOUS ADOPTIVE CELL THERAPY TARGETING NEOANTIGENS IN SOLID TUMORS
|Genocea Biosciences, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
GEN-011 is an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, the cancer proteins that are already recognized by the patient's T cells are found. Then, immune cells that recognize these cancer proteins are multiplied many times to create the GEN-011 cell therapy. The personalized GEN-011 is then given back to the patient in one or more intravenous (IV - into the vein) infusions. Cancers may include bladder cancer, kidney cancer, lung cancer, colon and rectal cancer, head and neck/oral cancer, and melanoma.
This study is closed
Mark Stein, MD
|Are you at least 18 years old?
|Is your life expectancy greater than 6 months?